Objective Systemic sclerosis is a connective tissue disease characterised by vasculopathy, tissue infi ltration of mononuclear cells and fi brosis of skin and inner organs. Mechanisms of fi brogenesis are unknown so far. Under normal circumstances matrix metalloproteinases and their inhibitors (TIMPs) regulate accumulation of extra cellular matrix components in skin. This regulation seems to be disturbed in SSc. Our aims are to investigate the effect of SSc patient serum on healthy circulating monocytes and to identify serum factors that contribute to the TIMP/MMP imbalance. Osteopontin has been identifi ed to be more abundant in patients with SSc and lung fi brosis. As osteopontin has been described to induce TIMP-1 in peripheral blood mononuclear cells (PBMCs) it is of potential interest in TIMP regulation. The results might give us some insight into the role of monocytes in SSc skin fi brosis. As novel gene which may be of interest in SSc we have identifi ed TWIST-1 as potential candidate. TWIST-1 has been described as transcription factor and negative regulator of TIMP-1. Methods We collected PBMCs and serum from SSc patients (limited and diffuse). CD14 monocytes were isolated by positive selection and mRNA levels of TIMP-1 were determined with q-RTPCR. Monocytes from healthy donors were cultured with serum from SSc patients and TIMP-1 and TWIST-1 were subsequently investigated by q-RTPCR and ELISA, respectively, or q-RTPCR only (TWIST-1). Furthermore we investigated osteopontin (OPN) as a candidate cytokine for inducing TIMP-1 expression. Results mRNA levels of TIMP-1 in SSc CD14 monocytes were signifi cantly upregulated compared to healthy controls. Serum from SSc patients, but not from RA patients or healthy controls, induced TIMP-1 production of healthy monocytes. Osteopontin was more abundant in SSc serum than in healthy controls and we have identifi ed OPN as potential activator for TIMP-1 production. Furthermore we found TWIST-1 expression levels in healthy monocytes treated with SSc serum less expressed than in controls. Interestingly OPN seems to repress TWIST-1 expression which could explain the increasing TIMP-1 expression. Conclusion Osteopontin seems to be an important candidate and must be investigated further. As TWIST-1 is a negative regulator of TIMP-1 it is possible that the more abundant OPN levels in SSc serum repress TWIST-1 and thereby promote TIMP-1 expression. This would point OPN out as potential drug target to treat SSc patients.
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